Expiration date: 11/2025

rectal suppositories are torpedo-shaped, from white to yellow in color, with an air rod or funnel-shaped recess allowed on the cut.

1 suppositorie contains:

prostate extract* 30 mg

zinc arginyl-glycinate dihydrochloride (in terms of arginyl-glycinate) 180 mg

* Prostatilen ® substance is a prostate extract with the addition of glycine.

Excipients: liquid paraffin-60 mg, solid fat (Vitepsol or Estaram, brand W35) - sufficient amount to obtain a suppository weighing 1.9 g.

5 PCs. - packaging sells contoured (1) - packs of cardboard.

5 PCs. - packaging sells contoured (2) - packs of cardboard.

Note: raw materials for the production of Prostatilen ® substance are obtained from farms where there are no animal diseases of viral, prion, bacterial and mycoplasmic etiology.

Pharmacological action

A drug of animal origin. It has an organotropic effect on the prostate gland. Reduces the degree of edema, leukocyte infiltration of the prostate, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secret of acinuses, stimulates the muscle tone of the bladder. Reduces thrombus formation, has antiplatelet activity, prevents the development of thrombosis venules in the prostate gland.

It has an anti-inflammatory, antioxidant effect, reduces pain.

It increases the level of free testosterone, increases the number of progressively mobile forms of spermatozoa and their morphologically normal forms. Causes a decrease in the level of antisperm antibodies. Normalizes the male copulative function.

Pharmacokinetics

Peptides of prostate extract in tissues are broken down by cellular proteases to amino acids, which are involved in the synthesis of tissue-specific proteins and other biologically active compounds. The chelated complex of zinc arginyl-glycinate dihydrochloride is broken down into zinc, arginine and glycine with their subsequent metabolism.

The drug does not have a cumulative effect.

Indications

• chronic abacterial prostatitis, including with impaired spermatogenesis and erectile function,
• conditions before and after prostate surgery,
• benign prostatic hyperplasia.